Editorial: Immunogenicity of Proteins Used as Therapeutics

Front Immunol. 2020 Oct 29:11:614856. doi: 10.3389/fimmu.2020.614856. eCollection 2020.

¹ Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
² Translational Medicine and Early Development, Sanofi Research and Development, Sanofi, Framingham, MA, United States.
³ Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
⁴ Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom.
⁵ Laboratory of Immunology, Division of Biotechnology Product Review and Research 3, Office of Biotechnology Products, Center for Drugs Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.

No abstract available

Keywords: drug development; drug safety; immune tolerance; immunogenicity; therapeutic proteins.

Publication types